Esketamine for treating treatment-resistant depression: Appraisal consultation document

DRAFT guidance does not recommend esketamine with SSRI or SNRI for treating adults with treatment-resistant depression that has not responded to at least 2 different antidepressants, as it was not considered a cost-effective use of NHS resources.


National Institute for Health and Care Excellence